Why the study?
Does intratracheal administration of AdCMVeNOS reduce pulmonary arterial pressure and pulmonary vascular resistance in eNOS-deficient mice?
Does intratracheal administration of AdCMVeNOS reduce pulmonary arterial pressure and pulmonary vascular resistance in eNOS-deficient mice?
In vivo gene transfer of eNOS to the lung partially restores normal pulmonary arterial pressure and vascular resistance in eNOS-deficient mice, suggesting a potential therapeutic approach for pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Supports eNOS gene transfer in preclinical PH models; leaves open translation to human disease.
It has been shown that mice deficient in the gene coding for endothelial nitric-oxide synthase (eNOS) have increased pulmonary arterial pressure and pulmonary vascular resistance. In the present study, the effect of transfer to the lung of an adenoviral vector encoding the eNOS gene (AdCMVeNOS) on pulmonary arterial pressure and pulmonary vascular resistance was investigated in eNOS-deficient mice. One day after intratracheal administration of AdCMVeNOS to eNOS(-/-) mice, there was an increase in eNOS protein, cGMP levels, and calcium-dependent conversion of l-arginine to l-citrulline in the lung. The increase in eNOS protein and activity in eNOS(-/-) mice was associated with a reduction in mean pulmonary arterial pressure and pulmonary vascular resistance when compared with values in eNOS-deficient mice treated with vehicle or a control adenoviral vector coding for beta-galactosidase, AdCMVbetagal. These data suggest that in vivo gene transfer of eNOS to the lung in eNOS(-/-) mice can increase eNOS staining, eNOS protein, calcium-dependent NOS activity, and cGMP levels and partially restore pulmonary arterial pressure and pulmonary vascular resistance to near levels measured in eNOS(+/+) mice. Thus, the major finding in this study is that in vivo gene transfer of eNOS to the lung in large part corrects a genetic deficiency resulting from eNOS deletion and may be a useful therapeutic intervention for the treatment of pulmonary hypertensive disorders in which eNOS activity is reduced.
No takes yet. Share an insight, caveat, or question.
Champion et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: